CLAIMS

1. A recombinant *Mycobacerium bovis* Bacillus Calmette-Guérin (BCG) cell from strain Danish subtype Prague derived from the parental strain *Mycobacerium bovis* TMC1025PCG Prague (ATCC35742), which is a urease-deficient cell and which comprises a recombinant nucleic acid molecule encoding a fusion polypeptide comprising:
(a) a domain from a Mycobacterium polypeptide, which is antigen (Ag) 85B or Ag85A or a fragment thereof, capable of eliciting an immune response, and
(b) a Listeria phagolysosomal escape domain
for use as vaccine against tuberculosis for generating a Th17 immune response.

2. The cell of claim 1 for the use of claim 1, wherein the domain capable of eliciting an immune response is selected from immunogenic peptides or polypeptides from *M*. *bovis* or *M. tuberculosis*.

3. The cell of any one of claims 1 or 2 for the use of claim 1 for generating a Th17 immune response in a mammalian, e.g. human subject.

4. The cell of any one of claims 1-3 for the use of claim 1 for generating a Th17 immune response in a Mycobacterium-naïve subject or a subject pre-exposed to Mycobacterium challenge.

5. The cell of any one of claims 1-4 for the use as a vaccine for generating a Th17 and further for generating a Th1 immune response.

6. Use of a recombinant *Mycobacterium bovis (*BCG) cell from strain Danish subtype Prague derived from the parental strain Mycobacterium *bovis* TMC1025BCG Prague (ATCC35742), which is a urease-deficient cell, in the manufacture of a vaccine against tuberculosis which comprises a recombinant nucleic acid molecule encoding a fusion polypeptide comprising:
(a) a domain from a Mycobacterium polypeptide, which is antigen (Ag) 85B or Ag85A or a fragment thereof, capable of eliciting an immune response, and
(b) a Listeria phagolysosomal
for generating a Th17 immune response in a subject in need thereof.